Diabetic Retinopathy - Pathophysiology to Treatment: A Review

Randhir      Singh; Aditya      Walia; Jasleen      Kaur; Praveen      Kumar; Inderjeet      Verma; Nidhi      Rani
Abstract

Diabetic retinopathy (DR) is a microvascular disease affecting the eyes of diabetic patients, and is the most prevalent complication of diabetes mellitus. Vision improvement is not possible in the majority of DR patients. Several studies have indicated that microvascular changes, inflammation, oxidative stress, and retinal neurodegeneration are involved in the pathogenesis of DR. Therefore, there is an urgent need for the development of new and effective treatment for DR. Understanding the molecular mechanisms involved in the pathogenesis of disease will pave a way for better treatment and management of DR. This article has emphasized the molecular pathogenesis and treatment of DR.
[1]
Retinopathy - Causes, Symptoms, Treatment, Diagnosis. 0000.  Available from:
          https://medbroadcast.com/condition/getcondition/retinopathy

[2]
Retinopathy Guide: Causes, Symptoms and Treatment Options. 0000.  Available from:
          https://myvision.org/retinopathy/

[3]
Brown AC, Nwanyanwu K. Retinopathy of Prematurity. Treasure Island, FL: StatPearls Publishing 2022.

[4]
Shukla UV, Tripathy K. Diabetic Retinopathy. Treasure Island, FL: StatPearls 2023.

[5]
Lisa J. Retinopathy of Prematurity. In:  Retina. 5th ed. W.B. Saunders 2013.
 [http://dx.doi.org/10.1016/B978-1-4557-0737-9.00114-4]

[6]
Mollie GW, William FM, Patricia A, Mago-Shah DD, Elizabeth B. The care of the premature infant, reference module. In: Biomedical Sciences. Elsevier 2021.
 [http://dx.doi.org/10.1016/B978-0-12-818872-9.00037-6]

[7]
Wong TY, McIntosh R. Hypertensive retinopathy signs as risk indicators of cardiovascular morbidity and mortality. Br Med Bull  2005; 73-74(1): 57-70.
 [http://dx.doi.org/10.1093/bmb/ldh050] [PMID:  16148191]

[8]
Semeraro F, Morescalchi F, Russo A, et al. Central serous chorioretinopathy: pathogenesis and management. Clin Ophthalmol  2019; 13: 2341-52.
 [http://dx.doi.org/10.2147/OPTH.S220845] [PMID:  31819359]

[9]
Iacono P, Toto L, Costanzo E, Varano M, Parravano MC. Pharmacotherapy of central serous chorioretinopathy: A review of the current treatments. Curr Pharm Des  2019; 24(41): 4864-73.
 [http://dx.doi.org/10.2174/1381612825666190123165914] [PMID:  30674250]

[10]
Lewis AS. Macular degeneration, glaucoma, and diabetic retinopathy: A continuing education program. MONTANASTATE UNIVERSITY- BOZEMAN Bozeman Montana 1999.

[11]
Kumar KPS, Bhowmik D, Harish G, Duraivel S, Kumar P. Diabetic retinopathy- symptoms, causes, risk factors and treatment. Pharm J  2018; 8(1)

[12]
Alam U, Asghar O, Azmi S, Malik RA. General aspects of diabetes mellitus. Handb Clin Neurol  2014; 126: 211-22.
 [http://dx.doi.org/10.1016/B978-0-444-53480-4.00015-1] [PMID:  25410224]

[13]
Watkins PJ. ABC of diabetes: Retinopathy. BMJ  2003; 326(7395): 924-6.
 [http://dx.doi.org/10.1136/bmj.326.7395.924] [PMID:  12714476]

[14]
Soumya D, Srilatha B. Late-stage complications of diabetes and insulin resistance. J Diabetes Metab  2011; 2(9): 1000167.

[15]
Harun NH, Yusof Y, Hassan F, Embong Z. Classification of fundus images for diabetic retinopathy using artificial neural network. 2019; IEEE Jordan International Joint Conference on Electrical Engineering and Information Technology (JEEIT)  498-501.
 [http://dx.doi.org/10.1109/JEEIT.2019.8717479]

[16]
Priya PV, Srinivasarao A, Sharma JV. Diabetic retinopathy-can lead to complete blindness. Int J Sci Invent Today  2013; 2(4): 254-65.

[17]
Wat N, Wong RLM, Wong IYH. Associations between diabetic retinopathy and systemic risk factors. Hong Kong Med J  2016; 22(6): 589-99.
 [http://dx.doi.org/10.12809/hkmj164869] [PMID:  27779095]

[18]
Capitão M, Soares R. Angiogenesis and inflammation crosstalk in diabetic retinopathy. J Cell Biochem  2016; 117(11): 2443-53.
 [http://dx.doi.org/10.1002/jcb.25575] [PMID:  27128219]

[19]
Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes  2005; 54(6): 1615-25.

[20]
Bek T. Diameter changes of retinal vessels in diabetic retinopathy. Curr Diab Rep  2017; 17(10): 82.
 [http://dx.doi.org/10.1007/s11892-017-0909-9] [PMID:  28791532]

[21]
Naruse K, Nakamura J, Hamada Y, et al. Aldose reductase inhibition prevents glucose-induced apoptosis in cultured bovine retinal microvascular pericytes. Exp Eye Res  2000; 71(3): 309-15.
 [http://dx.doi.org/10.1006/exer.2000.0882] [PMID:  10973739]

[22]
Romeo G, Liu WH, Asnaghi V, Kern TS, Lorenzi M. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes  2002; 51(7): 2241-8.
 [http://dx.doi.org/10.2337/diabetes.51.7.2241] [PMID:  12086956]

[23]
Ejaz S, Chekarova I, Ejaz A, Sohail A, Lim CW. Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy. Diabetes Obes Metab  2008; 10(1): 53-63.
 [PMID:  17941874]

[24]
Beltramo E, Porta M. Pericyte loss in diabetic retinopathy: Mechanisms and consequences. Curr Med Chem  2013; 20(26): 3218-25.
 [http://dx.doi.org/10.2174/09298673113209990022] [PMID:  23745544]

[25]
Huang H, He J, Johnson DK, et al. Deletion of placental growth factor prevents diabetic retinopathy and is associated with Akt activation and HIF1α-VEGF pathway inhibition. Diabetes  2015; 64(1): 200-12.
 [http://dx.doi.org/10.2337/db14-0016] [PMID:  25187372]

[26]
Lupo G, Motta C, Giurdanella G, et al. Role of phospholipases A2 in diabetic retinopathy: in vitro and in vivo studies. Biochem Pharmacol  2013; 86(11): 1603-13.
 [http://dx.doi.org/10.1016/j.bcp.2013.09.008] [PMID:  24076420]

[27]
Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem  1999; 274(33): 23463-7.
 [http://dx.doi.org/10.1074/jbc.274.33.23463] [PMID:  10438525]

[28]
Patel JI, Hykin PG, Gregor ZJ, Boulton M, Cree IA. Angiopoietin concentrations in diabetic retinopathy. Br J Ophthalmol  2005; 89(4): 480-3.
 [http://dx.doi.org/10.1136/bjo.2004.049940] [PMID:  15774928]

[29]
Rangasamy S, Srinivasan R, Maestas J, McGuire PG, Das A. A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy. Invest Ophthalmol Vis Sci  2011; 52(6): 3784-91.
 [http://dx.doi.org/10.1167/iovs.10-6386] [PMID:  21310918]

[30]
Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci  1999; 96(19): 10836-41.
 [http://dx.doi.org/10.1073/pnas.96.19.10836] [PMID:  10485912]

[31]
Yuuki T, Kanda T, Kimura Y, et al. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications  2001; 15(5): 257-9.
 [http://dx.doi.org/10.1016/S1056-8727(01)00155-6] [PMID:  11522500]

[32]
Schröder S, Palinski W, Schmid-Schönbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol  1991; 139(1): 81-100.
 [PMID:  1713023]

[33]
Miyamoto K, Hiroshiba N, Tsujikawa A, Ogura Y. In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci  1998; 39(11): 2190-4.
 [PMID:  9761301]

[34]
Joussen AM, Poulaki V, Mitsiades N, et al. Suppression of Fas‐FasL‐induced endothelial cell apoptosis prevents diabetic blood‐retinal barrier breakdown in a model of streptozotocin‐induced diabetes. FASEB J  2003; 17(1): 76-8.
 [http://dx.doi.org/10.1096/fj.02-0157fje] [PMID:  12475915]

[35]
Barouch FC, Miyamoto K, Allport JR, et al. Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci  2000; 41(5): 1153-8.
 [PMID:  10752954]

[36]
Chibber R, Ben-Mahmud BM, Coppini D, Christ E, Kohner EM. Activity of the glycosylating enzyme, core 2 GlcNAc (beta1,6) transferase, is higher in polymorphonuclear leukocytes from diabetic patients compared with age-matched control subjects: Relevance to capillary occlusion in diabetic retinopathy. Diabetes  2000; 49(10): 1724-30.
 [http://dx.doi.org/10.2337/diabetes.49.10.1724] [PMID:  11016457]

[37]
Kasza M, Meleg J, Várdai J, et al. Plasma E-selectin levels can play a role in the development of diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol  2017; 255(1): 25-30.
 [http://dx.doi.org/10.1007/s00417-016-3411-1] [PMID:  27377657]

[38]
Limb GA, Hickman-Casey J, Hollifield RD, Chignell AH. Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci  1999; 40(10): 2453-7.
 [PMID:  10476819]

[39]
Suzuki Y, Nakazawa M, Suzuki K, Yamazaki H, Miyagawa Y. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol  2011; 55(3): 256-63.
 [http://dx.doi.org/10.1007/s10384-011-0004-8] [PMID:  21538000]

[40]
Koleva-Georgieva DN, Sivkova NP, Terzieva D. Serum inflammatory cytokines IL-1β, IL-6, TNF-α and VEGF have influence on the development of diabetic retinopathy. Folia Med (Plovdiv)  2011; 53(2): 44-50.
 [http://dx.doi.org/10.2478/v10153-010-0036-8] [PMID:  21797106]

[41]
Boss JD, Singh PK, Pandya HK, et al. Assessment of neurotrophins and inflammatory mediators in vitreous of patients with diabetic retinopathy. Invest Ophthalmol Vis Sci  2017; 58(12): 5594-603.
 [http://dx.doi.org/10.1167/iovs.17-21973] [PMID:  29084332]

[42]
Abcouwer SF. Müller cell–microglia cross talk drives neuroinflammation in diabetic retinopathy. Diabetes  2017; 66(2): 261-3.
 [http://dx.doi.org/10.2337/dbi16-0047] [PMID:  28108606]

[43]
Sorrentino FS, Allkabes M, Salsini G, Bonifazzi C, Perri P. The importance of glial cells in the homeostasis of the retinal microenvironment and their pivotal role in the course of diabetic retinopathy. Life Sci  2016; 162: 54-9.
 [http://dx.doi.org/10.1016/j.lfs.2016.08.001] [PMID:  27497914]

[44]
Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest  1998; 102(4): 783-91.
 [http://dx.doi.org/10.1172/JCI2425] [PMID:  9710447]

[45]
Kowluru RA, Koppolu P. Diabetes-induced activation of caspase-3 in retina: effect of antioxidant therapy. Free Radic Res  2002; 36(9): 993-9.
 [http://dx.doi.org/10.1080/1071576021000006572] [PMID:  12448825]

[46]
Podestà F, Romeo G, Liu WH, et al. Bax is increased in the retina of diabetic subjects and is associated with pericyte apoptosis in vivo and in vitro. Am J Pathol  2000; 156(3): 1025-32.
 [http://dx.doi.org/10.1016/S0002-9440(10)64970-X] [PMID:  10702418]

[47]
El-Asrar AMA, Dralands L, Missotten L, Al-Jadaan IA, Geboes K. Expression of apoptosis markers in the retinas of human subjects with diabetes. Invest Ophthalmol Vis Sci  2004; 45(8): 2760-6.
 [http://dx.doi.org/10.1167/iovs.03-1392] [PMID:  15277502]

[48]
Tien T, Zhang J, Muto T, Kim D, Sarthy VP, Roy S. High glucose induces mitochondrial dysfunction in retinal müller cells: Implications for diabetic retinopathy. Invest Ophthalmol Vis Sci  2017; 58(7): 2915-21.
 [http://dx.doi.org/10.1167/iovs.16-21355] [PMID:  28586916]

[49]
Sasaki M, Ozawa Y, Kurihara T, et al. Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes. Diabetologia  2010; 53(5): 971-9.
 [http://dx.doi.org/10.1007/s00125-009-1655-6] [PMID:  20162412]

[50]
Sohn EH, van Dijk HW, Jiao C, et al. Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. Proc Natl Acad Sci  2016; 113(19): E2655-64.
 [http://dx.doi.org/10.1073/pnas.1522014113] [PMID:  27114552]

[51]
van Dijk HW, Kok PHB, Garvin M, et al. Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci  2009; 50(7): 3404-9.
 [http://dx.doi.org/10.1167/iovs.08-3143] [PMID:  19151397]

[52]
Tracy TS. Bilberry.  In: Herbal Products.  Toxicology and Clinical Pharmacology 2007; pp. 259-68.

[53]
Bansal M, Singh N, Pal S, Dev I, Ansari KM. Chemopreventive role of dietary phytochemicals in colorectal cancer. Adv Mol Toxicol  2018; 12: 69-121.
 [http://dx.doi.org/10.1016/B978-0-444-64199-1.00004-X]

[54]
Suryanarayana P, Saraswat M, Mrudula T, Krishna TP, Krishnaswamy K, Reddy GB. Curcumin and turmeric delay streptozotocin-induced diabetic cataract in rats. Invest Ophthalmol Vis Sci  2005; 46(6): 2092-9.
 [http://dx.doi.org/10.1167/iovs.04-1304] [PMID:  15914628]

[55]
Xu Z, Sun T, Li W, Sun X. Inhibiting effects of dietary polyphenols on chronic eye diseases. J Funct Foods  2017; 39: 186-97.
 [http://dx.doi.org/10.1016/j.jff.2017.10.031]

[56]
Ikonne EU, Ikpeazu VO, Ugbogu EA. The potential health benefits of dietary natural plant products in age related eye diseases. Heliyon  2020; 6(7): e04408.
 [http://dx.doi.org/10.1016/j.heliyon.2020.e04408] [PMID:  32685729]

[57]
Rice-evans CA, Miller NJ, Bolwell PG, Bramley PM, Pridham JB. The relative antioxidant activities of plant-derived polyphenolic flavonoids. Free Radic Res  1995; 22(4): 375-83.
 [http://dx.doi.org/10.3109/10715769509145649] [PMID:  7633567]

[58]
Gan RY, Li HB, Sui ZQ, Corke H. Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): An updated review. Crit Rev Food Sci Nutr  2018; 58(6): 924-41.
 [http://dx.doi.org/10.1080/10408398.2016.1231168] [PMID:  27645804]

[59]
Keylor MH, Matsuura BS, Stephenson CRJ. Chemistry and biology of resveratrol-derived natural products. Chem Rev  2015; 115(17): 8976-9027.
 [http://dx.doi.org/10.1021/cr500689b] [PMID:  25835567]

[60]
Gambini J, Inglés M, Olaso G, et al. Properties of resveratrol: in vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans. Oxid Med Cell Longev  2015; 2015: 837042.

[61]
Kim YH, Kim YS, Roh GS, Choi WS, Cho GJ. Resveratrol blocks diabetes-induced early vascular lesions and vascular endothelial growth factor induction in mouse retinas. Acta Ophthalmol  2012; 90(1): e31-7.
 [http://dx.doi.org/10.1111/j.1755-3768.2011.02243.x] [PMID:  21914146]

[62]
Yar AS, Menevse S, Dogan I, et al. Investigation of ocular neovascularization-related genes and oxidative stress in diabetic rat eye tissues after resveratrol treatment. J Med Food  2012; 15(4): 391-8.
 [http://dx.doi.org/10.1089/jmf.2011.0135] [PMID:  22191573]

[63]
Yang PM, Wu ZZ, Zhang YQ, Wung BS. Lycopene inhibits ICAM-1 expression and NF-κB activation by Nrf2-regulated cell redox state in human retinal pigment epithelial cells. Life Sci  2016; 155: 94-101.
 [http://dx.doi.org/10.1016/j.lfs.2016.05.006] [PMID:  27155396]

[64]
Kronschläger M, Löfgren S, Yu Z, Talebizadeh N, Varma SD, Söderberg P. Caffeine eye drops protect against UV-B cataract. Exp Eye Res  2013; 113: 26-31.
 [http://dx.doi.org/10.1016/j.exer.2013.04.015] [PMID:  23644096]

[65]
Kaczmarczyk-Sedlak I, Folwarczna J, Sedlak L, et al. Effect of caffeine on biomarkers of oxidative stress in lenses of rats with streptozotocin-induced diabetes. Arch Med Sci  2019; 15(4): 1073-80.
 [http://dx.doi.org/10.5114/aoms.2019.85461] [PMID:  31360202]

[66]
Varma S. Effect of coffee (caffeine) against human cataract blindness. Clin Ophthalmol  2016; 10: 213-20.
 [http://dx.doi.org/10.2147/OPTH.S96394] [PMID:  26869755]

[67]
Zhang S, Zhou R, Li B, et al. Caffeine preferentially protects against oxygen‐induced retinopathy. FASEB J  2017; 31(8): 3334-48.
 [http://dx.doi.org/10.1096/fj.201601285R] [PMID:  28420694]

[68]
Chu KO, Pang CP. Herbal molecules in eye diseases. Taiwan J Ophthalmol  2014; 4(3): 103-9.
 [http://dx.doi.org/10.1016/j.tjo.2014.03.005]

[69]
Kowluru RA, Zhong Q, Santos JM, Thandampallayam M, Putt D, Gierhart DL. Beneficial effects of the nutritional supplements on the development of diabetic retinopathy. Nutr Metab  2014; 11(1): 8.
 [http://dx.doi.org/10.1186/1743-7075-11-8] [PMID:  24479616]

[70]
Kowluru RA, Menon B, Gierhart DL. Beneficial effect of zeaxanthin on retinal metabolic abnormalities in diabetic rats. Invest Ophthalmol Vis Sci  2008; 49(4): 1645-51.
 [http://dx.doi.org/10.1167/iovs.07-0764] [PMID:  18385086]

[71]
Muriach M, Bosch-Morell F, Alexander G, et al. Lutein effect on retina and hippocampus of diabetic mice. Free Radic Biol Med  2006; 41(6): 979-84.
 [http://dx.doi.org/10.1016/j.freeradbiomed.2006.06.023] [PMID:  16934681]

[72]
Zampatti S, Ricci F, Cusumano A, Marsella LT, Novelli G, Giardina E. Review of nutrient actions on age-related macular degeneration. Nutr Res  2014; 34(2): 95-105.
 [http://dx.doi.org/10.1016/j.nutres.2013.10.011] [PMID:  24461310]

[73]
Andreatta W, El-Sherbiny S. Evidence-based nutritional advice for patients affected by age-related macular degeneration. Ophthalmologica  2014; 231(4): 185-90.
 [http://dx.doi.org/10.1159/000357528] [PMID:  24821294]

[74]
Chiu CJ, Taylor A. Nutritional antioxidants and age-related cataract and maculopathy. Exp Eye Res  2007; 84(2): 229-45.
 [http://dx.doi.org/10.1016/j.exer.2006.05.015] [PMID:  16879819]

[75]
Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more. Free Radic Biol Med  2007; 43(1): 4-15.
 [http://dx.doi.org/10.1016/j.freeradbiomed.2007.03.024] [PMID:  17561088]

[76]
Strobel M, Tinz J, Biesalski HK. The importance of β-carotene as a source of vitamin A with special regard to pregnant and breastfeeding women. Eur J Nutr  2007; 46(S1): 1-20.
 [http://dx.doi.org/10.1007/s00394-007-1001-z] [PMID:  17665093]

[77]
Mansour SE, Browning DJ, Wong K, Flynn HW Jr, Bhavsar AR. The evolving treatment of diabetic retinopathy. Clin Ophthalmol  2020; 14: 653-78.
 [http://dx.doi.org/10.2147/OPTH.S236637] [PMID:  32184554]

[78]
Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology  2005; 112(10): 1747-57.
 [http://dx.doi.org/10.1016/j.ophtha.2005.06.007] [PMID:  16154196]

[79]
Economic costs of diabetes in the U.S. in 2012. Diabetes Care  2013; 36(4): 1033-46.
 [http://dx.doi.org/10.2337/dc12-2625] [PMID:  23468086]

[80]
Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology  2010; 117(6): 1064-1077.e35.
 [http://dx.doi.org/10.1016/j.ophtha.2010.02.031] [PMID:  20427088]

[81]
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med  2015; 372(13): 1193-203.

[82]
Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology  2016; 123(6): 1351-9.

[83]
Virgili G, Parravano M, Menchini F, Evans JR. Anti‐vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev  2014; 2014(10): CD007419.
 [http://dx.doi.org/10.1002/14651858.CD007419.pub4]

[84]
Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina  2006; 26(8): 859-70.
 [http://dx.doi.org/10.1097/01.iae.0000242842.14624.e7] [PMID:  17031284]

[85]
Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res  2007; 85(4): 425-30.
 [http://dx.doi.org/10.1016/j.exer.2007.05.008] [PMID:  17714704]

[86]
Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis  2012; 15(2): 171-85.
 [http://dx.doi.org/10.1007/s10456-011-9249-6] [PMID:  22302382]

[87]
Stewart MW. A review of ranibizumab for the treatment of diabetic retinopathy. Ophthalmol Ther  2017; 6(1): 33-47.
 [http://dx.doi.org/10.1007/s40123-017-0083-9] [PMID:  28324452]

[88]
Khan Z, Kuriakose RK, Khan M, Chin EK, Almeida DRP. Efficacy of the intravitreal sustained-release dexamethasone implant for diabetic macular edema refractory to anti-vascular endothelial growth factor therapy: Meta-analysis and clinical implications. Ophthalmic Surg Lasers Imaging Retina  2017; 48(2): 160-6.
 [http://dx.doi.org/10.3928/23258160-20170130-10] [PMID:  28195619]

[89]
Pacella F, Romano MR, Turchetti P, et al. An eighteen-month follow-up study on the effects of Intravitreal Dexamethasone Implant in diabetic macular edema refractory to anti-VEGF therapy. Int J Ophthalmol  2016; 9(10): 1427-32.
 [http://dx.doi.org/10.18240/ijo.2016.10.10] [PMID:  27803859]

[90]
Jonas JB, Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol  2001; 132(3): 425-7.
 [http://dx.doi.org/10.1016/S0002-9394(01)01010-8] [PMID:  11530068]

[91]
Jonas JB, Kreissig I, Söfker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol  2003; 121(1): 57-61.
 [http://dx.doi.org/10.1001/archopht.121.1.57] [PMID:  12523885]

[92]
Chase HP, Garg SK, Harris S, Hoops S, Jackson WE, Holmes DL. Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. Ann Ophthalmol  1993; 25(8): 284-9.
 [PMID:  8239321]

[93]
Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet  1998; 351(9095): 28-31.
 [http://dx.doi.org/10.1016/S0140-6736(97)06209-0] [PMID:  9433426]

[94]
Virk SA, Donaghue KC, Wong TY, Craig ME. Interventions for diabetic retinopathy in type 1 diabetes: Systematic review and meta-analysis. Am J Ophthalmol  2015; 160(5): 1055-1064.e4.
 [http://dx.doi.org/10.1016/j.ajo.2015.07.024] [PMID:  26210869]

[95]
Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: Randomised, placebo-controlled trials. Lancet  2008; 372(9647): 1394-402.
 [http://dx.doi.org/10.1016/S0140-6736(08)61412-9] [PMID:  18823656]

[96]
The Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report no. 4. Int Ophthalmol Clin  1987; 27(4): 265-72.
 [http://dx.doi.org/10.1097/00004397-198702740-00006] [PMID:  3692708]

[97]
Kumar KS, Bhowmik D, Harish G, Duraivel S, Kumar BP. Diabetic retinopathy-symptoms, causes, risk factors and treatment. Pharma Innov  2012; 1(8)
Cite As
Current Diabetes Reviews

Diabetic Retinopathy - Pathophysiology to Treatment: A Review

Abstract
